Search Results - "Chu, Quincy S."

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion by Chu, Quincy S.

“…The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful…”
Get full text

Supplementation with fish oil increases first‐line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer by Murphy, Rachel A., Mourtzakis, Marina, Chu, Quincy S. C., Baracos, Vickie E., Reiman, Tony, Mazurak, Vera C.

“…BACKGROUND: Palliative chemotherapy is aimed at increasing survival and palliating symptoms. However, the response rate to first‐line chemotherapy in patients…”
Get full text

Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy by Murphy, Rachel A., Mourtzakis, Marina, Chu, Quincy S.C., Baracos, Vickie E., Reiman, Tony, Mazurak, Vera C.

“…BACKGROUND: Involuntary weight loss is a major contributor to mortality and morbidity in patients with advanced cancer. Nutritional intervention with fish oil…”
Get full text

Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review by Khwaja, Raida M, Chu, Quincy S-C

“…Targeting the immune system, especially the PDL-1/PD-1 axis, has significantly improved the outcomes of metastatic lung cancer patients. However, only a…”
Get full text

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer by Melosky, Barbara L, Leighl, Natasha B, Dawe, David, Blais, Normand, Wheatley-Price, Paul F, Chu, Quincy S-C, Juergens, Rosalyn A, Ellis, Peter M, Sun, Alexander, Schellenberg, Devin, Ionescu, Diana N, Cheema, Parneet K

“…Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in…”
Get full text

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial by Besse, Benjamin, Pons-Tostivint, Elvire, Park, Keunchil, Hartl, Sylvia, Forde, Patrick M., Hochmair, Maximilian J., Awad, Mark M., Thomas, Michael, Goss, Glenwood, Wheatley-Price, Paul, Shepherd, Frances A., Florescu, Marie, Cheema, Parneet, Chu, Quincy S. C., Kim, Sang-We, Morgensztern, Daniel, Johnson, Melissa L., Cousin, Sophie, Kim, Dong-Wan, Moskovitz, Mor T., Vicente, David, Aronson, Boaz, Hobson, Rosalind, Ambrose, Helen J., Khosla, Sajan, Reddy, Avinash, Russell, Deanna L., Keddar, Mohamed Reda, Conway, James P., Barrett, J. Carl, Dean, Emma, Kumar, Rakesh, Dressman, Marlene, Jewsbury, Philip J., Iyer, Sonia, Barry, Simon T., Cosaert, Jan, Heymach, John V.

“…For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy…”
Get full text

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC by Cheema, Parneet K, Banerji, Shantanu O, Blais, Normand, Chu, Quincy S-C, Juergens, Rosalyn A, Leighl, Natasha B, Sacher, Adrian, Sheffield, Brandon S, Snow, Stephanie, Vincent, Mark, Wheatley-Price, Paul F, Yip, Stephen, Melosky, Barbara L

“…Activating mutations in , in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic…”
Get full text

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies by MITA, Monica M, MITA, Alain C, KNOWLES, Heather, RIVERA, Victor M, KREISBERG, Jeff, BEDROSIAN, Camille L, TOLCHER, Anthony W, CHU, Quincy S, ROWINSKY, Eric K, FETTERLY, Gerald J, GOLDSTON, Michelle, PATNAIK, Amita, MATHEWS, Lesley, RICART, Alejandro D, MAYS, Theresa

“…This phase I trial was conducted to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP23573;…”
Get full text

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies by Goel, Sanjay, Mita, Alain C, Mita, Monica, Rowinsky, Eric K, Chu, Quincy S, Wong, Nancy, Desjardins, Christopher, Fang, Fang, Jansen, Mendel, Shuster, Dale E, Mani, Sridhar, Takimoto, Chris H

“…Purpose: Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analogue of halichondrin B that acts…”
Get full text

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer by Daoud, Alia, Chu, Quincy S

“…Discovery of the epidermal growth factor receptor gene mutation and the anaplastic lymphoma kinase chromosomal translocation in non-small cell lung cancer has…”
Get full text

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib by Meza-Junco, Judith, Chu, Quincy S.-C, Christensen, Olaf, Rajagopalan, Prabhu, Das, Soma, Stefanyschyn, Ruslan, Sawyer, Michael B

“…Purpose To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib…”
Get full text

Canadian Consensus Recommendations on the Management of MET -Altered NSCLC by Cheema, Parneet K, Banerji, Shantanu O, Blais, Normand, Chu, Quincy S-C, Desmeules, Patrice, Juergens, Rosalyn A, Leighl, Natasha B, Sheffield, Brandon S, Wheatley-Price, Paul F, Melosky, Barbara L

“…In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces,…”
Get full text

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer by Ionescu, Diana N, Stockley, Tracy L, Banerji, Shantanu, Couture, Christian, Mather, Cheryl A, Xu, Zhaolin, Blais, Normand, Cheema, Parneet K, Chu, Quincy S-C, Melosky, Barbara, Leighl, Natasha B

“…Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC…”
Get full text

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours by Devriese, Lot A., Koch, Kevin M., Mergui-Roelvink, Marja, Matthys, Gemma M., Ma, Wen Wee, Robidoux, Andre, Stephenson, Joe J., Chu, Quincy S. C., Orford, Keith W., Cartee, Leanne, Botbyl, Jeff, Arya, Nikita, Schellens, Jan H. M.

“…Summary Aim To quantify the effect of food on the systemic exposure of lapatinib at steady state when administered 1 h before and after meals, and to observe…”
Get full text

Profiling Determinants of Resting Energy Expenditure in Colorectal Cancer by Purcell, Sarah A., Baracos, Vickie E., Chu, Quincy S.C., Sawyer, Michael B., Severin, Diane, Mourtzakis, Marina, Lieffers, Jessica R., Prado, Carla M.

“…Background: Understanding resting energy expenditure (REE) is important for determining energy requirements; REE might be altered in individuals with cancer…”
Get full text

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas by Chu, Quincy S C, Forouzesh, Bahram, Syed, Samira, Mita, Monica, Schwartz, Garry, Cooper, Joshua, Copper, Joshua, Curtright, Janet, Rowinsky, Eric K

“…This phase II study evaluated the antitumor activity of the tetracycline analog COL-3, a potent inhibitor of metalloproteinases (MMPs), particularly MMP-2 and…”
Get full text

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors by MITA, Alain C, HAMMOND, Lisa A, WEITMAN, Steve, ROWINSKY, Eric K, BONATE, Peter L, WEISS, Geoffrey, MCCREERY, Heather, SYED, Samira, GARRISON, Mitchell, CHU, Quincy S. C, DEBONO, Johann S, JONES, Christopher B

“…Purpose: To determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of tasidotin (ILX651), a novel…”
Get full text

Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies by CHU, Quincy S. C, SCHWARTZ, Garry, HO, Peter T. C, ROWINSKY, Eric K, DE BONO, Johann, SMITH, Deborah A, KOCH, Kevin M, VERSOLA, Melissa J, PANDITE, Lini, ARYA, Nikita, CURTRIGHT, Jan, FLEMING, Ronald A

“…This phase I trial (EGF10005) assessed the safety, optimally tolerated regimen (OTR), and pharmacokinetics of lapatinib and capecitabine in combination in…”
Get full text

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer by Wander, Seth A, Cohen, Ofir, Gong, Xueqian, Johnson, Gabriela N, Buendia-Buendia, Jorge E, Lloyd, Maxwell R, Kim, Dewey, Luo, Flora, Mao, Pingping, Helvie, Karla, Kowalski, Kailey J, Nayar, Utthara, Waks, Adrienne G, Parsons, Stephen H, Martinez, Ricardo, Litchfield, Lacey M, Ye, Xiang S, Yu, Chunping, Jansen, Valerie M, Stille, John R, Smith, Patricia S, Oakley, Gerard J, Chu, Quincy S, Batist, Gerald, Hughes, Melissa E, Kremer, Jill D, Garraway, Levi A, Winer, Eric P, Tolaney, Sara M, Lin, Nancy U, Buchanan, Sean G, Wagle, Nikhil

“…Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR ) breast cancer have not been clearly…”
Get more information

Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study by RICART, Alejandro D, SARANTOPOULOS, John, CALVO, Emiliano, CHU, Quincy S, GREENE, Douglas, NATHAN, Faith E, PETRONE, Michael E, TOLCHER, Anthony W, PAPADOPOULOS, Kyriakos P

“…Purpose: The study aimed to assess the pharmacokinetic behavior of satraplatin under fasted and fed conditions, and its safety and preliminary antitumor…”
Get full text